Hardman Johnston Global Advisors LLC Buys 288,160 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Hardman Johnston Global Advisors LLC boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 22.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,566,430 shares of the company’s stock after purchasing an additional 288,160 shares during the quarter. Hardman Johnston Global Advisors LLC owned about 0.32% of Elanco Animal Health worth $18,969,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in ELAN. Blue Trust Inc. boosted its position in Elanco Animal Health by 2,129.2% during the third quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after purchasing an additional 3,790 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Elanco Animal Health by 70.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 19,515 shares of the company’s stock worth $287,000 after purchasing an additional 8,077 shares during the period. Country Club Bank bought a new stake in Elanco Animal Health during the third quarter worth approximately $1,925,000. New World Advisors LLC boosted its position in Elanco Animal Health by 28.0% during the third quarter. New World Advisors LLC now owns 25,800 shares of the company’s stock worth $379,000 after purchasing an additional 5,650 shares during the period. Finally, Hedges Asset Management LLC boosted its position in Elanco Animal Health by 33.8% during the third quarter. Hedges Asset Management LLC now owns 95,500 shares of the company’s stock worth $1,403,000 after purchasing an additional 24,100 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 1.0 %

NYSE:ELAN opened at $11.02 on Monday. Elanco Animal Health Incorporated has a fifty-two week low of $10.77 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $5.45 billion, a PE ratio of 27.54, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The business’s 50-day simple moving average is $11.80 and its 200-day simple moving average is $13.10.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research reports. Stifel Nicolaus reduced their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley reduced their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Barclays increased their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Finally, UBS Group started coverage on Elanco Animal Health in a research report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and an average price target of $16.00.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.